ArticleCancer2009
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Article in Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.International journal of hematology · 2025Trial
- Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2023Trial
- Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.Blood advances · 2022Trial
- Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations.Blood advances · 2025Article
- How I treat secondary acute myeloid leukemia.Blood · 2025Review
- Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML.Blood cancer journal · 2024Article
- Adult rhabdomyosarcoma combined with acute myeloid leukemia: A case report.World journal of clinical cases · 2024Article
- Therapy-related core binding factor acute myeloid leukemia.International journal of hematologic oncology · 2023Review
- Oncology stewardship in acute myeloid leukemia.Annals of hematology · 2022Review
- Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.Blood cancer discovery · 2022Article
- Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.American journal of hematology · 2022Article
- Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".Blood cancer journal · 2022Article
- Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Core binding factor acute myelogenous leukemia-2021 treatment algorithm.Blood cancer journal · 2021Review
- Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.Current hematologic malignancy reports · 2021Review
- Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.American journal of blood research · 2021Review
- Review
- Review
- Treatment Strategies for Therapy-related Acute Myeloid Leukemia.Clinical lymphoma, myeloma & leukemia · 2020Review
- Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTherapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities.
methodsA total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%.
resultsPatients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis.
conclusionsMatched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.